Facebook Linkedin RSS Twitter Youtube
Home 2019

Roche company

Roche to Expand Fibrotic Disease Pipeline with Up-to-$1.4B Promedior Acquisition
Industry News

Roche to Expand Fibrotic Disease Pipeline with Up-to-$1.4B Promedior Acquisition

On Higher Ground: The Dilemma on Gene Therapy Pricing
GEN Edge

On Higher Ground: The Dilemma on Gene Therapy Pricing

Development to Manufacturing: Considerations for Optimizing mRNA Production
Featured

Development to Manufacturing: Considerations for Optimizing mRNA Production

Top 10 M&A Deals of January–June 2019
A-Lists

Top 10 M&A Deals of January–June 2019

Sanofi Cuts 466 Jobs, Limits Cardiovascular and Diabetes R&D
Drug Discovery

Sanofi Cuts 466 Jobs, Limits Cardiovascular and Diabetes R&D

Genmab Files for $500M U.S. IPO, Seeking to Launch a Proprietary Treatment by 2025
Cancer

Genmab Files for $500M U.S. IPO, Seeking to Launch a Proprietary Treatment by 2025

Roche Extends Offer for Spark Therapeutics a Second Time, as Shareholders Balk at Tender Offer
Genome Editing

Roche Extends Offer for Spark Therapeutics a Second Time, as Shareholders Balk at Tender Offer

Roche-Licensed Rare Disease Drug at Center of Ipsen’s Up-to-$1.3B Clementia Acquisition
Featured

Roche-Licensed Rare Disease Drug at Center of Ipsen’s Up-to-$1.3B Clementia Acquisition

Roche Expands into Gene Therapy with Planned $4.8B Acquisition of Spark Therapeutics
Featured

Roche Expands into Gene Therapy with Planned $4.8B Acquisition of Spark Therapeutics

The Art of Biotech Customization
Featured

The Art of Biotech Customization

1...567...55Page 6 of 55
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.